RZONF.US Rize Oncology Inc.

Healthcare Biotechnology USA Stocks
0.0004 USD
Close of Nov 15, 2026
0.0004 0.0004
Market cap
USD 32.3K
P/E
-
P/B
0.03x
ROE
-49.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2024.

Is RZONF.US undervalued?

Graham number

The Graham number of Rize Oncology Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rize Oncology Inc. fundamental analysis

No fundamental analysis for Rize Oncology Inc. yet.

Rize Oncology Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rize Oncology Inc.

Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, other types of cancers, and certain proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 an…

Full company profile